Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1.

[1]  Veronika Rockova,et al.  Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. , 2011, Blood.

[2]  N. Friedman,et al.  Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis , 2011, Cell.

[3]  R. Hills,et al.  Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial , 2010, Blood cancer journal.

[4]  K. Kang,et al.  Amurensin G, a Potent Natural SIRT1 Inhibitor, Rescues Doxorubicin Responsiveness via Down-Regulation of Multidrug Resistance 1 , 2010, Molecular Pharmacology.

[5]  U. Mony,et al.  Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia , 2010, Leukemia.

[6]  K. Akashi,et al.  FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. , 2009, Blood.

[7]  N. Russell,et al.  FLT3‐ITD expression levels and their effect on STAT5 in AML with and without NPM mutations , 2009, British journal of haematology.

[8]  N. Russell,et al.  Impaired S-Phase Arrest in Acute Myeloid Leukemia Cells with a FLT3 Internal Tandem Duplication Treated with Clofarabine , 2009, Clinical Cancer Research.

[9]  U. Banerjee,et al.  Reactive Oxygen Species prime Drosophila haematopoietic progenitors for differentiation , 2009, Nature.

[10]  R. Hills,et al.  The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial , 2009, British journal of haematology.

[11]  K. Kang,et al.  Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. , 2008, Carcinogenesis.

[12]  C. Bloomfield,et al.  High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. , 2008, Blood.

[13]  N. Russell,et al.  Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials , 2007, Clinical Cancer Research.

[14]  D. Gilliland,et al.  FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. , 2007, Cell stem cell.

[15]  D. Tindall,et al.  Dynamic FoxO transcription factors , 2007, Journal of Cell Science.

[16]  S. Armstrong,et al.  FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress , 2007, Cell.

[17]  N. Casadevall,et al.  Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[18]  N. Russell,et al.  DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412 , 2006, Leukemia.

[19]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[20]  V. Chow,et al.  Microarray and real-time RT-PCR analyses of a novel set of differentially expressed human genes in ECV304 endothelial-like cells infected with dengue virus type 2. , 2006, Journal of virological methods.

[21]  Chunaram Choudhary,et al.  Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. , 2005, Cancer research.

[22]  Eleanor Woodward,et al.  Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. , 2005, Biochemical and biophysical research communications.

[23]  L. N. Valenti,et al.  Nuclear Trapping of the Forkhead Transcription Factor FoxO1 via Sirt-dependent Deacetylation Promotes Expression of Glucogenetic Genes* , 2005, Journal of Biological Chemistry.

[24]  S. Nicosia,et al.  Suppression of FOXO1 activity by FHL2 through SIRT1‐mediated deacetylation , 2005, The EMBO journal.

[25]  M. Pallis,et al.  Flow cytometric measurement of functional and phenotypic P-glycoprotein. , 2005, Methods in molecular medicine.

[26]  N. Russell,et al.  The expression of P‐glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors , 2004, British journal of haematology.

[27]  D. Mahadevan,et al.  Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. , 2004, Blood.

[28]  B. Löwenberg,et al.  Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. , 2004, Blood.

[29]  J. Griffin,et al.  FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins , 2004, Oncogene.

[30]  Steven P. Gygi,et al.  Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase , 2004, Science.

[31]  Delin Chen,et al.  Mammalian SIRT1 Represses Forkhead Transcription Factors , 2004, Cell.

[32]  K. Scotto.  Transcriptional regulation of ABC drug transporters , 2003, Oncogene.

[33]  Zhijian Qian,et al.  Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  N. Russell,et al.  P-glycoprotein in Acute Myeloid Leukaemia: Therapeutic Implications of its Association With Both a Multidrug-resistant and an Apoptosis-resistant Phenotype , 2002, Leukemia & lymphoma.

[35]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[36]  M. Pallis,et al.  P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. , 2000, Blood.

[37]  P. Hokland,et al.  Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t(12;21) TEL‐AML1 fusion transcript , 1999, Genes, chromosomes & cancer.

[38]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[39]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.